![Andre Gross](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Andre Gross is associated with the firm cytena GmbH as the Chief Technology Officer since 2014.
He is also the founder of the same company, which was established in 2014.
Actieve functies van Andre Gross
Bedrijven | Functie | Begin |
---|---|---|
cytena GmbH
![]() cytena GmbH BiotechnologyHealth Technology cytena GmbH develops a device for separating of single cells. It has developed a device called cy-Clone to separate single cells and these single cells are required for the development of state-of-the-art drugs, so-called biologicals as well as for the genetic analysis of single cells for cancer and stem cell research, the cy-Clone is supported by an automated imaging process to encapsulate cells in droplets, which are delivered to any type of substrate. The company was founded by Peter Koltay, Benjamin Steimle, Jonas Schoendube and Andre Gross in August 2014 and is headquartered in Freiburg, Germany. | Oprichter | 01-06-2014 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
cytena GmbH
![]() cytena GmbH BiotechnologyHealth Technology cytena GmbH develops a device for separating of single cells. It has developed a device called cy-Clone to separate single cells and these single cells are required for the development of state-of-the-art drugs, so-called biologicals as well as for the genetic analysis of single cells for cancer and stem cell research, the cy-Clone is supported by an automated imaging process to encapsulate cells in droplets, which are delivered to any type of substrate. The company was founded by Peter Koltay, Benjamin Steimle, Jonas Schoendube and Andre Gross in August 2014 and is headquartered in Freiburg, Germany. | Health Technology |